ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

empagliflozin

Also written as “BI 10773”, “Empagliflozin” and “BI10773”.

Its studies are mostly in Diabetes Mellitus, Type 2 · Heart Failure · Diabetes Mellitus, Type 1 · Renal Insufficiency, Chronic · Diabetes Mellitus, Lipoatrophic, led by 15 companies.

Drug pageEmpagliflozin: every studyMany companies study it; this page follows only the 124 they lead. All 404 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Oct 27, 2015124 company-led studies, 8 open or runningNext primary completion: Dec 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Boehringer Ingelheim992 open or runningphase 4since Oct 27, 2015Nov 14, 2007Dec 11, 2026phase 1 · NCT07845630
ADIUMits history only40 open or runningno phasesince Mar 9, 2026Mar 9, 2026none ahead
Getz Pharmaits history only41 open or runningphase 4since Nov 27, 2020Nov 27, 2020Dec 31, 2026phase 4 · NCT05164263
Gedeon Richter Plc.its history only30 open or runningphase 1since Dec 10, 2024Dec 10, 2024none ahead
Chong Kun Dang Pharmaceuticalits history only21 open or runningphase 4since Jan 15, 2026Aug 1, 2016Aug 2027phase 4 · NCT07365358
Dong Wha Pharmaceuticalits history only20 open or runningphase 1since Apr 10, 2023Apr 10, 2023none ahead
Kobe Universityits history only20 open or runningphase 3since Jul 10, 2019Jul 10, 2019none ahead
Celltrionits history only11 open or runningphase 3since Jun 30, 2025Jun 30, 2025Dec 2026phase 3 · NCT07093476
Dong-A STits history only10 open or runningphase 1since Dec 5, 2018Dec 5, 2018none ahead
Genuine Research Center, Egyptits history only10 open or runningphase 1since Nov 16, 2021Nov 16, 2021none ahead

Also a collaborator on its studies: Eli Lilly.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Boehringer Ingelheim only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 46 studies since Jan 24, 2013.

  1. Jul 10, 2018Phase 3 study in Renal Insufficiency, ChronicNCT03594110 · 6,609 enrolled · United States, Canada, China and more
  2. Aug 9, 2018Phase 1 study in HealthyNCT03629054 · 30 enrolled · Germany
  3. Nov 4, 2019Phase 3 study in Heart FailureNCT04157751 · 530 enrolled · United States, Belgium, Canada and more
  4. Jan 16, 2020Phase 3 study in Diabetes Mellitus, Type 2NCT04233801 · 219 enrolled · China
  5. Aug 10, 2020Phase 3 study in Myocardial InfarctionNCT04509674 · 6,522 enrolled · United States, Argentina, Australia and more
  6. Aug 26, 2020Phase 4 study in Diabetes Mellitus, Type 2NCT04531462 · 129 enrolled · Japan
  7. Oct 6, 2021Phase 1 study in HealthyNCT05083949 · 32 enrolled · Brazil
  8. Jan 5, 2022Phase 2 study in Renal Insufficiency, ChronicNCT05182840 · 714 enrolled · United States, Argentina, Australia and more
  9. Apr 11, 2025Phase 2 study in Renal Insufficiency, ChronicNCT06926660 · 492 enrolled · United States, Argentina, Australia and more
  10. Apr 30, 2025Phase 1 study in HealthyNCT06962826 · 14 enrolled · Germany
  11. Jun 17, 2025Phase 1 study in HealthyNCT07035457 · 15 enrolled · Germany
  12. Aug 5, 2025Phase 3 study in Renal Insufficiency, ChronicNCT07107945 · 135 enrolled · United States, Argentina, Australia and more
  13. Aug 19, 2025Phase 1 study in HealthyNCT07133399 · 32 enrolled · Germany
  14. Sep 23, 2026Phase 1 study in HealthyNCT07845630 · 36 planned · Germany

Ahead

  1. Dec 11, 2026Primary completion: phase 1 study in HealthyNCT07845630
  2. Apr 16, 2027Primary completion: phase 3 study in Renal Insufficiency, ChronicNCT07107945

TargetBeta

SLC5A2 →read by rule
“An orally available competitive inhibitor of sodium-glucose co-transporter 2 (SGLT2; SLC5A2) with antihyperglycemic activity”NCIt, by rule
“Sodium/glucose cotransporter 2 inhibitor”ChEMBL 37, by rule

Other programs on SLC5A2

ProgramCompanyFurthest phaseStudies
dapagliflozinAstraZenecaphase 4133
ertugliflozinruleMerckphase 422
vicadrostatBoehringer Ingelheimphase 316
Empagliflozin/LinagliptinruleHumanis Saglık Anonim Sirketiphase 12

Studies

The newest 60 of 99 Boehringer Ingelheim leads. Each opens its study page. Every study on its drug page →

StudyPhaseStatusPrimary completionSize
NCT07845630Healthy · Germany1RecruitingDec 11, 202636
NCT07133399Healthy · Germany1CompletedOct 22, 202532
NCT07107945Renal Insufficiency, Chronic · United States, Argentina, Australia and more3Active, not recruitingApr 16, 2027135
NCT07035457Healthy · Germany1CompletedAug 7, 202515
NCT06962826Healthy · Germany1CompletedJun 26, 202514
NCT06926660Renal Insufficiency, Chronic · United States, Argentina, Australia and more2CompletedAug 14, 2026492
NCT05182840Renal Insufficiency, Chronic · United States, Argentina, Australia and more2CompletedJun 19, 2023714
NCT05083949Healthy · Brazil1CompletedAug 6, 202132
NCT04531462Diabetes Mellitus, Type 2 · Japan4CompletedAug 19, 2022129
NCT04509674Myocardial Infarction · United States, Argentina, Australia and more3CompletedNov 5, 20236,522
NCT04233801Diabetes Mellitus, Type 2 · China3CompletedMar 3, 2022219
NCT04157751Heart Failure · United States, Belgium, Canada and more3CompletedMay 28, 2021530
NCT03629054Healthy · Germany1CompletedNov 5, 201830
NCT03594110Renal Insufficiency, Chronic · United States, Canada, China and more3CompletedJul 5, 20226,609
NCT03448419Heart Failure · United States, Australia, Canada and more3CompletedSep 30, 2019312
NCT03448406Heart Failure · United States, Australia, Canada and more3CompletedOct 4, 2019315
NCT03429543Diabetes Mellitus, Type 2 · United States, Argentina, Brazil and more3CompletedOct 19, 2022175
NCT03332212Heart Failure · United Kingdom3CompletedMay 21, 202072
NCT03259490Healthy · Germany1CompletedNov 13, 201730
NCT03057977Heart Failure · United States, Argentina, Australia and more3CompletedMay 1, 20203,730
NCT03057951Heart Failure · United States, Argentina, Australia and more3CompletedApr 26, 20215,988
NCT02821910Healthy · Germany1CompletedOct 1, 201650
NCT02815644Healthy · Japan1CompletedOct 5, 201622
NCT02782624Healthy · Germany1CompletedNov 200916
NCT02758171Healthy · Germany1CompletedJul 29, 201656
NCT02702011Diabetes Mellitus, Type 1 · Japan2CompletedSep 5, 201648
NCT02632747Diabetes Mellitus, Type 1 · Canada2CompletedDec 19, 201731
NCT02589639Diabetes Mellitus, Type 2 · Japan4CompletedApr 18, 2017269
NCT02589626Diabetes Mellitus, Type 2 · Japan4CompletedJun 2, 201765
NCT02580591Diabetes Mellitus, Type 1 · United States, Australia, Canada and more3CompletedSep 12, 2017977
NCT02577315Healthy · Russian Federation1CompletedOct 201525
NCT02489968Diabetes Mellitus, Type 2 · Japan3CompletedNov 18, 2016880
NCT02453555Diabetes Mellitus, Type 2 · Japan3CompletedAug 26, 2016275
NCT02414958Diabetes Mellitus, Type 1 · United States, Australia, Austria and more3CompletedApr 20, 2017730
NCT02276365Healthy1CompletedJul 200920
NCT02266472Healthy · Germany1CompletedDec 201430
NCT02230995Healthy · Germany1CompletedOct 201430
NCT02182830Diabetes Mellitus, Type 2 · United States3CompletedMay 18, 2017166
NCT02182453Healthy1CompletedAug 200848
NCT02172274Healthy1CompletedJul 20088
NCT02172261Healthy1CompletedJun 200916
NCT02172248Healthy1CompletedMar 200916
NCT02172235Healthy1CompletedJul 201020
NCT02172222Healthy1CompletedSep 200916
NCT02172209Healthy1CompletedFeb 200814
NCT02172196Healthy1CompletedJul 200916
NCT02172170Healthy1CompletedMar 200772
NCT02121483Diabetes Mellitus, Type 2 · United States, France, Israel and more1CompletedFeb 201627
NCT02106923Healthy · United States1CompletedJun 201472
NCT02102932Healthy · China1CompletedAug 201496
NCT02028767Healthy · Canada1CompletedFeb 201432
NCT01984606Diabetes Mellitus, Type 23WithdrawnFeb 20170
NCT01975220Healthy · United States1CompletedDec 201372
NCT01947855Diabetes Mellitus, Type 2 · Japan3CompletedDec 201360
NCT01924767Diabetes Mellitus, Type 2 · Germany1CompletedNov 200748
NCT01907113Diabetes Mellitus, Type 2 · Germany1CompletedDec 200940
NCT01867307Diabetes Mellitus, Type 2 · United States2CompletedOct 201539
NCT01844531Healthy · Germany1CompletedNov 201324
NCT01811953Healthy · Germany1CompletedMay 201348
NCT01778049Diabetes Mellitus, Type 2 · United States, Argentina, Australia and more3CompletedMar 2015708

How it is read

Names in the registry

  • “BI 10773”, 71 entries
  • “Empagliflozin”, 53 entries
  • “BI10773”, 7 entries
  • “Empagliflozin/Metformin”, 4 entries
  • “Empagliflozin + Linagliptin”, 4 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.